MOF breaking higher as anticipatedThe MOF did indeed break out north as was suggested by the technicals.
Having hit resistance from several weeks ago, price has stalled and appears to be now waiting for the 200 EMA to catch up.
I expect price to drift sideways for several days now and when the 200 EMA is met then we could see price use the 200 as a springboard to break the resistance and move higher.
The picture remains BULLISH and MOF still represents very good value at these levels.
Molecular
MOF (Molecular Future) posied to break out one way or anotherMolecular Future has (apparently) arrested its steady decline for the last 8 weeks and is tracking sideways.
Price is now trapped between a rising trend line and the 200 EMA in a clear flag or pennant formation.
Which way it breaks is anyones guess but it looks as if we shall see price break out either up or down over the next few days.
I remain mildly BULLISH on MOF based on its performance before the asset was forked (diluted).
As a trading opportunity the picture is mixed but asa a hodling opportunity I think that at .00085 cents this is a very cheap asset and certainly one thats worth buying a few hundred dollars worth and forgetting about.
Molecular Data Inc. $MKD - Long idea 💡 ⚠️ This idea is based on my technical analysis only. Do your research and trade on your own risk!
looking for bottom buy on MKD for long term equity holdMolecular Data has plenty of insider holdings, as well as institutional, signifying continued faith in the companies future prospects. The institutional shares at ~16% could pose a selling hazard eventually, as MKD doesn't have history of growth, if the company fails to deliver upon expectations. At the same time, such a large number shows obvious interest for a company with such a small market cap. So what appears as a double-edged sword, feels more purely beneficial to me. Nullifying further risk, the institutions hold less than either the public or the insiders respectively- at 18% and 21%. There is not enough data to see recent insider selling and buying, however, Dongliang Chang (Top Key Executive) appears to hold a whopping 13% of shares outstanding. Notably, 57% of the company's stock is held by just 5 entities.
Analyst predict 27% growth for the company over the next 1-3 years, but MKD earnings have supposedly been declining 20% a year since listing. Shares have also been diluted by 20% this past year, according to my research.
So back we are again to a double-edged sword. MKD does have a PT of $9, listed at $6 in Dec. '19, and is currently trading ~.82c a share.
One thing that is certain- in this market there are limitless amounts of overvalued, poorly structured companies' shares available for purchase. And with most all of them getting positive Price Action in this recent bull market, MKD has not received the same amount of attention and has plenty of room to rise.
As a small account trader, i own just 50 shares @.85c. This is NOT a recommendation to trade MKD in any manner whatsoever.
Molecular Data $MKD - investment idea 💡 ✅ - The volume healthy 12.206M (3.733M average)
✅ - We got double bottom on daily
✅ - We got Bulish Hammer 🔨 price action on 4h
✅ - MACD
✅ - STOCH
✅ - DeMarker
❌ - MA50 (8.40% under 50MA)
❌ - Pivots: 4.61% under the pivot point
⏰ - Breakout at 0.93
🚀 - Potential target (🚀+65%, 🚀🚀+167%, 🚀🚀🚀+400%)
🪂 - If things goes wrong better to exit under 0.78
⚠️ - This idea is based on my technical analysis only. Do your research and trade on your own risk!
BIOC Cancer Diagnostics Eliminates Biopsies with Blood TestBlood diagnostic OncoCEE-BR was used by Columbia University College of Physicians and Surgeons in New York City to aid cancer patients' diagnosis. Involved biopsies are no longer required, cancer can be detected with a simple blood test. The chart has strong bullish divergence, has just made a breakout with an initial target around 4 dollars.
